ResMed
339 hedge funds and large institutions have $6.76B invested in ResMed in 2017 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 135 increasing their positions, 129 reducing their positions, and 54 closing their positions.
670% more call options, than puts
Call options by funds: $26.8M | Put options by funds: $3.48M
8% more capital invested
Capital invested by funds: $6.25B → $6.76B (+$511M)
5% more repeat investments, than reductions
Existing positions increased: 135 | Existing positions reduced: 129
0.14% less ownership
Funds ownership: 61.37% → 61.23% (-0.14%)
9% less funds holding
Funds holding: 374 → 339 (-35)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
59% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 54
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$110M |
| 2 |
BlackRock
New York
|
+$64.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.1M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$16.5M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$14.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$41M |
| 2 |
HSBC Holdings
London,
United Kingdom
|
-$27.3M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$19.9M |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
-$13.3M |
| 5 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$11.9M |
RMD Hedge Fund Activity: Q2 2017 in Review
339 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q2 2017, worth a combined $6.76B — up 8.2% from $6.25B a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of RMD and 22 opened new positions — a net loss of 32 holders — while 129 trimmed existing stakes and 135 added.
The largest buyer was Fidelity Investments, adding an estimated $110M. The largest seller was Morgan Stanley, cutting an estimated $41M.
- 339 institutional investors held ResMed (RMD) as of Q2 2017, down from 374 in Q1 2017.
- Funds reported $6.76B of ResMed stock for Q2 2017, up 8.2% quarter-over-quarter.
- 22 funds opened new ResMed positions in Q2 2017 and 54 closed out, a net change of -32 holders.
- The largest ResMed buyer in Q2 2017 was Fidelity Investments, an estimated $110M added.
- The largest ResMed seller in Q2 2017 was Morgan Stanley, an estimated $41M sold.
Based on aggregated 13F filings for Q2 2017.